For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2018
Summary
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 4, 16 and 4 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Central Nervous System, Immunology, Cardiovascular, Dermatology, Ear Nose Throat Disorders, Genito Urinary System And Sex Hormones, Respiratory, Mouth and Dental Disorders, Musculoskeletal Disorders, Ophthalmology and Other Diseases which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Liver Fibrosis, Sepsis, Atherosclerosis, Atopic Dermatitis, Breast Cancer, Dengue Fever, Drug Addiction, Kidney Fibrosis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Acute Pain, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Bacterial Sepsis, Burns, Cervical Cancer, Chronic Back Pain, Chronic Liver Disease, Complicated Intra-Abdominal Infections, Crohn's Disease (Regional Enteritis), Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Epilepsy, Escherichia coli Infections, Follicular Lymphoma, Globoid Cell Leukodystrophy (Krabbe Disease), Hearing Disorders, Human Papillomavirus (HPV) Associated Cancer, Inflammatory Bowel Disease, Ischemia Reperfusion Injury, Keratoconjunctivitis sicca (Dry Eye), Leishmaniasis (Kala-Azar), Listeriosis, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Opium (Opioid) Addiction, Opium Withdrawal Syndrome, Osteoarthritis, Ovarian Cancer, Pain, Pancreatic Cancer, Peanut Allergy, Phlebovirus Infections, Post-Traumatic Stress Disorder (PTSD), Postherpetic Neuralgia, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Recurrent Glioblastoma Multiforme (GBM), Rhinitis, Rosacea, Secondary Progressive Multiple Sclerosis (SPMS), Septic Shock, Solid Tumor, Trauma, Wounds, Xerostomia and Zika Virus Infections.
The latest report Toll Like Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope